Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KOD 
Kodiak Sciences Inc (KOD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: KOD (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 244.7% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 134.72M USD | Price to earnings Ratio - | 1Y Target Price 6.67 |
Price to earnings Ratio - | 1Y Target Price 6.67 | ||
Volume (30-day avg) 323698 | Beta 2.26 | 52 Weeks Range 2.19 - 11.60 | Updated Date 04/1/2025 |
52 Weeks Range 2.19 - 11.60 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.35 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.864 | Actual -0.84 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.66% | Return on Equity (TTM) -84.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49880686 | Price to Sales(TTM) - |
Enterprise Value 49880686 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding 52623800 | Shares Floating 32340149 |
Shares Outstanding 52623800 | Shares Floating 32340149 | ||
Percent Insiders 4.64 | Percent Institutions 80.28 |
Analyst Ratings
Rating 3.12 | Target Price 6.67 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 3 | Sell 3 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kodiak Sciences Inc
Company Overview
History and Background
Kodiak Sciences Inc. is a biopharmaceutical company founded in 2006. It focuses on developing novel therapeutics to treat chronic, high-prevalence retinal diseases. The company has evolved from its initial research stages to clinical development of its lead product candidate, tarcocimab tedromer.
Core Business Areas
- Retinal Disease Therapeutics: Kodiak Sciences focuses primarily on developing therapies for retinal diseases such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Leadership and Structure
Kodiak Sciences is led by Victor Perlroth, MD, as CEO. The company has a board of directors and a management team overseeing research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Tarcocimab Tedromer: Tarcocimab tedromer is Kodiak Sciences' lead product candidate, an anti-VEGF antibody biopolymer conjugate being developed for the treatment of wet AMD, DME, and RVO. It is designed to provide extended durability compared to existing anti-VEGF therapies. As it is in clinical trials, no current market share or revenue can be given. Competitors include Eylea (Regeneron), Lucentis (Roche/Genentech), Beovu (Novartis) and Vabysmo (Roche).
Market Dynamics
Industry Overview
The retinal disease therapeutics market is large and growing, driven by an aging population and increasing prevalence of diabetes. The market is dominated by anti-VEGF therapies, but there is a need for more durable and effective treatments.
Positioning
Kodiak Sciences aims to differentiate itself by developing tarcocimab tedromer, which is designed for longer-lasting efficacy compared to existing anti-VEGF drugs, potentially reducing the frequency of injections. It is positioned as a potential next-generation therapy in the retinal disease market.
Total Addressable Market (TAM)
The global wet AMD market alone is expected to reach billions of dollars annually. Kodiak's success depends on how many patients it can help with Tarcocimab vs existing solutions
Upturn SWOT Analysis
Strengths
- Novel technology platform (ABC Platform)
- Potentially longer-lasting therapy (Tarcocimab)
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Clinical trial risk
- Single product pipeline reliance
- High cash burn rate
- Dependent on regulatory approval
- No current revenue
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other retinal diseases
- Potential for premium pricing due to durability
Threats
- Competition from established anti-VEGF therapies
- Failure of clinical trials
- Regulatory hurdles
- Generic entry of existing therapies
- New entrants with novel technologies
Competitors and Market Share
Key Competitors
- REGN
- BAYRY
- NVS
- RHHBY
Competitive Landscape
Kodiak Sciences faces intense competition from established players in the anti-VEGF market. Its competitive advantage hinges on demonstrating superior durability and efficacy with tarcocimab tedromer.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the progress of its clinical development programs and the expansion of its pipeline.
Future Projections: Future growth is contingent on the successful development and commercialization of tarcocimab tedromer and other pipeline candidates.
Recent Initiatives: Recent initiatives focus on advancing tarcocimab tedromer through Phase 3 clinical trials and exploring additional indications.
Summary
Kodiak Sciences is a development-stage biopharmaceutical company with no current revenue. It is heavily reliant on the success of its lead candidate, tarcocimab tedromer. Positive clinical trial results are critical for its future growth. Competition in the retinal disease therapeutics market is intense, requiring Kodiak to prove its drug's superiority.
Similar Companies
- REGN
- NVS
- RHHBY
- LLY
Sources and Disclaimers
Data Sources:
- Kodiak Sciences Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kodiak Sciences Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Chairman, CEO & President Dr. Victor Perlroth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 109 | Website https://kodiak.com |
Full time employees 109 | Website https://kodiak.com | ||
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.